Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
1. •Grady WM, Carethers JM: Gastroenterology 2008;135:1079–99. Genomic and epigenetic instability in colorectal cancer pathogen- esis. This is a useful summary of molecular pathways of oncogenesis.
2. Weisenberger DJ, Siegmund KD, Campan M, et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787–93.
3. •Young GP, Cole S: Which fecal occult blood test is best to screen for colorectal cancer? Nature Clinical Practice Gastroenterology and Hepatology, 2009;6:140–141. This is a succinct review of why fecal immunochemical tests should replace guaiac fecal occult blood tests in screening programs.
4. Mandel JS, Bond JH, Church TR, et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N.Engl.J.Med., 1993; 328: 1365–1371
5. Mandel JS, Church TR, Bond JH, et al.: The effect of fecal occult- blood screening on the incidence of colorectal cancer. N.Engl.J. Med., 2000; 343: 1603–1607
6. Atkin WS, Edwards R, Kralj-Hans I, et al.; UK Flexible Sigmoidoscopy Trial Investigators: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–33. This is the first unbiased population-based randomized trial to show without doubt that polyp detection and removal reduces incidence and mortality from colorectal cancer.
7. Bossuyt PM, Irwig L, Craig J, Glasziou P: Comparative accuracy: assessing new tests against existing diagnostic pathways BMJ. 2006;332:1089–1092.
8. Pepe MS, Etzioni R, Feng S, et al.: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061.
9. St John DJB, Young GP, Alexeyeff MA, et al.: Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993, 104, 1661–1668.
10. Smith A, Young GP, Cole SR, Bampton P: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152–2159
11. ••Young GP, Allison J: Colorectal cancer screening. In Textbook of Gastroenterology (5th edition), Eds Yamada T, Alpers D Kalloo AN, Kaplowitz N, Owyang C, Powell DW. Lippincott Williams and Wilkins, Philadelphia, 2009, 1598–1610. This is a comprehensive review of the evidence for screening for colorectal cancer and the pros and cons of the screening tests. This review takes a population-based approach with emphasis on engaging populations and feasibility.
12. Jones S, Chen WD, Parmigiani G, et al.: Comparative lesion sequencing provides insights into tumor evolution. Proc.Natl. Acad.Sci.U.S.A, 2008; 105: 4283–4288
13. ••Levin B, Lieberman DA, McFarland B, et al.; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570–95. These are the US guidelines on screening, with emphasis on polyps as a key strategy.
14. Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. New Engl J Med 1992 Mar 5;326(10):658–62.
15. Winawer SJ, Zauber AG, O’Brien MJ, et al.: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. New Engl J Med 1993 Apr 1;328(13):901–6.
16. Strope SA, Andriole GL: Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010 Sep;7(9):487–93.
17. Hermsen M, Postma C, Baak J, et al.: Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology, 2002;123:1109–1119.
18. Carvalho B, Postma C, Mongera S, et al.: Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut, 2009 Jan;58 (1):79–89
19. ••Bosch LJW, Carvalho B, Fijneman RJA, et al.: Molecular tests for colorectal cancer screening. Clin Colorectal Cancer 2011 Jan; in press. This is the best and most up-to-date review of the detail of molecular tests for colorectal cancer screening, having a more scientific focus. It also includes information on blood tests for screening.
20. Osborn NK , Ahlquist DA: Stool screening for colorectal cancer: molecular approaches. Gastroenterology, 2005; 128: 192–206
21. Théry C, Ostrowski M, Segura E: Membrane vesicles as convey- ors of immune response. Nat Rev Immunol. 2009;9:581–593.;
22. Ahlquist DA, Skoletsky JE, Boynton KA, et al.: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology, 2000; 119: 1219–1227
23. Boynton KA, Summerhayes IC, Ahlquist DA, et al.: DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin.Chem., 2003; 49: 1058–1065
24. Schuebel KE, Chen W, Cope L, et al.: Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS.Genet., 2007; 3: 1709–1723
25. •Calistri D, Rengucci C, Molinari C, et al.: Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. Cell Oncol., 
26. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al.: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N.Engl.J.Med., 2004; 351: 2704–2714]
27. ••Ahlquist DA, Sargent DJ, Loprinzi CL, et al.: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann.Intern.Med., 2008; 149: 441–50. This is a valuable comparison of fecal DNA tests with guaiac-faecal occult blood tests.